New Risk Model Targets Lung Disease Mortality
A new diagnostic tool could help clinicians better predict outcomes for patients with interstitial lung disease and hypertension.
Updated on Oct. 26, 2026 in Asthma
Live Poll
Should healthcare systems prioritize earlier diagnostic screening for patients with chronic lung conditions?
Researchers have presented interim findings from the PHINDER study, which evaluates a new scoring model to predict mortality for patients with interstitial lung disease and pulmonary hypertension. This prospective study assesses risk factors to help clinicians better identify high-risk patients who may require prioritized care.
Why it matters
Predicting disease progression is a critical challenge in managing complex lung conditions like idiopathic pulmonary fibrosis. This new model aims to improve clinical decision-making by quantifying risk for patients who face the dual burden of pulmonary fibrosis and hypertension.
This prospective, noninterventional study of 119 enrollees found that 12% of patients with idiopathic pulmonary fibrosis were classified as high-risk by the PVD-B65 model. These preliminary findings represent an early look at how this scoring system might eventually stratify patient outcomes.
The players
American College of Chest Physicians
A professional society focused on clinical chest medicine, education, and the advancement of treatments for respiratory and cardiovascular diseases.
The details
The PVD-B65 model assigns a risk score from 0 to 14 by evaluating several clinical markers including the presence of pulmonary fibrosis and pulmonary vascular resistance. It also incorporates physical performance through the 6-minute walk test and physiological stress via B-type natriuretic peptide levels. By combining these variables, researchers hope to provide a more accurate prognosis for patients with moderate-to-severe pulmonary arterial pressure.
Timeline
The FDA approved treprostinil for patients with PH-ILD in 2025.
Interim data from the PHINDER study were presented in October 2026.
Health Landscape
This research builds on the recent expansion of therapeutic options for patients with interstitial lung disease and pulmonary hypertension, such as the 2025 FDA approval of treprostinil for PH-ILD. It represents a shift toward more personalized risk stratification in a complex, multi-system condition.
Patients managing interstitial lung disease and pulmonary hypertension should discuss how their physicians currently assess risk during their checkups. It is worth asking how specific clinical markers, such as B-type natriuretic peptide levels or exercise tolerance, factor into your personalized care plan.
The takeaway
Predicting outcomes in interstitial lung disease is evolving toward more data-driven scoring models. If you have been diagnosed with these conditions, ask your specialist about the clinical metrics they use to track your disease progression and adjust your treatment strategy.
Further reading
Learn more about the latest innovations in managing respiratory conditions in our Asthma section.
Source note: This article includes information reported by Medscape.
Live Poll
Should healthcare systems prioritize earlier diagnostic screening for patients with chronic lung conditions?
